Last reviewed · How we verify

Aliskiren, Perindopril

Medical University of Gdansk · FDA-approved active Small molecule

Aliskiren, Perindopril is a Antihypertensive combination (direct renin inhibitor + ACE inhibitor) Small molecule drug developed by Medical University of Gdansk. It is currently FDA-approved for Hypertension. Also known as: Rasilez 300 mg, Prestarium 10 mg.

This combination lowers blood pressure by blocking the renin-angiotensin-aldosterone system through dual inhibition of renin and ACE.

This combination lowers blood pressure by blocking the renin-angiotensin-aldosterone system through dual inhibition of renin and ACE. Used for Hypertension.

At a glance

Generic nameAliskiren, Perindopril
Also known asRasilez 300 mg, Prestarium 10 mg
SponsorMedical University of Gdansk
Drug classAntihypertensive combination (direct renin inhibitor + ACE inhibitor)
TargetRenin and Angiotensin-Converting Enzyme (ACE)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Aliskiren is a direct renin inhibitor that blocks the first step of the renin-angiotensin cascade, while perindopril is an ACE inhibitor that prevents conversion of angiotensin I to angiotensin II. Together, they provide complementary inhibition of the pathway that regulates blood pressure and fluid balance, resulting in greater blood pressure reduction than either agent alone.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Aliskiren, Perindopril

What is Aliskiren, Perindopril?

Aliskiren, Perindopril is a Antihypertensive combination (direct renin inhibitor + ACE inhibitor) drug developed by Medical University of Gdansk, indicated for Hypertension.

How does Aliskiren, Perindopril work?

This combination lowers blood pressure by blocking the renin-angiotensin-aldosterone system through dual inhibition of renin and ACE.

What is Aliskiren, Perindopril used for?

Aliskiren, Perindopril is indicated for Hypertension.

Who makes Aliskiren, Perindopril?

Aliskiren, Perindopril is developed and marketed by Medical University of Gdansk (see full Medical University of Gdansk pipeline at /company/medical-university-of-gdansk).

Is Aliskiren, Perindopril also known as anything else?

Aliskiren, Perindopril is also known as Rasilez 300 mg, Prestarium 10 mg.

What drug class is Aliskiren, Perindopril in?

Aliskiren, Perindopril belongs to the Antihypertensive combination (direct renin inhibitor + ACE inhibitor) class. See all Antihypertensive combination (direct renin inhibitor + ACE inhibitor) drugs at /class/antihypertensive-combination-direct-renin-inhibitor-ace-inhibitor.

What development phase is Aliskiren, Perindopril in?

Aliskiren, Perindopril is FDA-approved (marketed).

What are the side effects of Aliskiren, Perindopril?

Common side effects of Aliskiren, Perindopril include Hyperkalemia, Dizziness, Fatigue, Cough, Hypotension.

What does Aliskiren, Perindopril target?

Aliskiren, Perindopril targets Renin and Angiotensin-Converting Enzyme (ACE) and is a Antihypertensive combination (direct renin inhibitor + ACE inhibitor).

Related